Literature DB >> 14696016

Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations.

Justin C Touchon1, Cynthia Moore, Julie Frederickson, Charles K Meshul.   

Abstract

A unilateral lesion of the rat nigrostriatal pathway with 6-hydroxydopamine (6-OHDA) results in a decrease in the basal extracellular level of striatal glutamate, a nearly complete loss of tyrosine hydroxylase (TH) immunolabeling, an increase in the density of glutamate immunogold labeling within nerve terminals making an asymmetrical synaptic contact, and an increase in the number of apomorphine-induced contralateral rotations. [Meshul et al. (1999) Neuroscience 88:1-16; Meshul and Allen (2000) Synapse 36:129-142]. In Parkinson's disease, a lesion of either the subthalamic nucleus (STN) or the motor thalamic nucleus relieves the patient of some of the motor difficulties associated with this disorder. In this rodent model, either the STN or motor thalamic nucleus was electrolytically destroyed 2 months following a unilateral 6-OHDA lesions. Following a lesion of either the STN or motor thalamic nucleus in 6-OHDA-treated rats, there was a significant decrease (40-60%) in the number of apomorphine-induced contralateral rotations compared to the 6-OHDA group. There was a significant decrease (<30%) in the basal extracellular level of striatal glutamate in all of the experimental groups compared to the sham group. Following an STN and/or 6-OHDA lesion, the decrease in striatal extracellular levels was inversely associated with an increase in the density of nerve terminal glutamate immunolabeling. There was no change in nerve terminal glutamate immunogold labeling in either the motor thalamic or motor thalamic plus 6-OHDA lesion groups compared to the sham group. The decrease in the number of apomorphine-induced rotations was not due to an increase in TH immunolabeling (i.e., sprouting) within the denervated striatum. This suggests that alterations in striatal glutamate appear not to be directly involved in the STN or motor thalamic lesion-induced reduction in contralateral rotations. Published 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14696016     DOI: 10.1002/syn.10306

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  6 in total

1.  Dietary therapy restores glutamatergic input to orexin/hypocretin neurons after traumatic brain injury in mice.

Authors:  Jonathan E Elliott; Samuel E De Luche; Madeline J Churchill; Cindy Moore; Akiva S Cohen; Charles K Meshul; Miranda M Lim
Journal:  Sleep       Date:  2018-03-01       Impact factor: 5.849

Review 2.  Exendin-4 for Parkinson's disease.

Authors:  Felipe de Jesús Esparza-Salazar; Alma Rosa Lezama-Toledo; Germán Rivera-Monroy; Cesario V Borlongan
Journal:  Brain Circ       Date:  2021-03-30

3.  In vivo brain microdialysis: advances in neuropsychopharmacology and drug discovery.

Authors:  Altaf S Darvesh; Richard T Carroll; Werner J Geldenhuys; Gary A Gudelsky; Jochen Klein; Charles K Meshul; Cornelis J Van der Schyf
Journal:  Expert Opin Drug Discov       Date:  2011-02       Impact factor: 6.098

4.  Lesion of the ventromedial nucleus of the thalamus blocks acute cocaine-induced changes in striatal glutamate.

Authors:  Brenda L McKee; Modjgan Keyghobadi; Adrienne P Tozier De La Poterie; Charles K Meshul
Journal:  Synapse       Date:  2010-06       Impact factor: 2.562

5.  PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease.

Authors:  Seong-Jin Yu; Shuchun Chen; Yung-Yung Yang; Elliot J Glotfelty; Jin Jung; Hee Kyung Kim; Ho-Il Choi; Doo-Sup Choi; Barry J Hoffer; Nigel H Greig; Yun Wang
Journal:  Front Neurosci       Date:  2020-08-11       Impact factor: 4.677

6.  Effects of subthalamic nucleus lesions and stimulation upon corticostriatal afferents in the 6-hydroxydopamine-lesioned rat.

Authors:  Ruth H Walker; Cindy Moore; Georgia Davies; Lisa B Dirling; Rick J Koch; Charles K Meshul
Journal:  PLoS One       Date:  2012-03-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.